Literature DB >> 8542248

Interferon-induced acute renal failure: a case report and literature review.

R Horowitz1, D Glicklich, L B Sablay, P H Wiernik, S Wadler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8542248     DOI： 10.1007/bf01571409

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  10 in total

1.  Interferon-induced reversible acute renal failure with nephrotic syndrome.

Authors:  S Nair; M S Ernstoff; R R Bahnson; S Arthur; J Johnston; M A Downs; J Neuhart; J M Kirkwood
Journal:  Urology       Date:  1992-02       Impact factor: 2.649

2.  Nephrotic syndrome during treatment with interferon.

Authors:  P Selby; J Kohn; J Raymond; I Judson; T McElwain
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

3.  Acute renal failure during therapy with recombinant human gamma interferon.

Authors:  B H Ault; F B Stapleton; L Gaber; A Martin; S Roy; S B Murphy
Journal:  N Engl J Med       Date:  1988-11-24       Impact factor: 91.245

4.  Acute renal failure during interferon treatment.

Authors:  I H Fahal; N Murry; P Chu; G M Bell
Journal:  BMJ       Date:  1993-04-10

5.  Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides.

Authors:  S D Averbuch; H A Austin; S A Sherwin; T Antonovych; P A Bunn; D L Longo
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

6.  Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.

Authors:  C Erlichman; R C Donehower; J L Speyer; R Klecker; B A Chabner
Journal:  J Natl Cancer Inst       Date:  1982-02       Impact factor: 13.506

7.  Systemic gamma-interferon therapy for recurrent gliomas.

Authors:  M S Mahaley; L Bertsch; S Cush; G Y Gillespie
Journal:  J Neurosurg       Date:  1988-12       Impact factor: 5.115

Review 8.  Clinical toxicity of interferons in cancer patients: a review.

Authors:  J R Quesada; M Talpaz; A Rios; R Kurzrock; J U Gutterman
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

9.  Unusual glomerular lesion in a patient receiving long-term interferon alpha.

Authors:  E Lederer; L Truong
Journal:  Am J Kidney Dis       Date:  1992-11       Impact factor: 8.860

10.  Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

Authors:  M R Cooper; A Fefer; J Thompson; D C Case; R Kempf; R Sacher; J Neefe; J Bickers; J H Scarffe; R Spiegel
Journal:  Cancer Treat Rep       Date:  1986-04
  10 in total
  5 in total

1.  Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C.

Authors:  D F Stein; A Ahmed; V Sunkhara; W Khalbuss
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 2.  Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature.

Authors:  M Colovic; V Jurisic; G Jankovic; D Jovanovic; L J Nikolic; J Dimitrijevic
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Samih H Nasr; M Barry Stokes; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

4.  An unusual case of acute kidney injury caused by obstructive uropathy revealing gastric cancer.

Authors:  Karima Boubaker; Mohamad Alkadi; Omar Fitouri; Ali Ibrahim Ali Rahil; Hassen Al Malki
Journal:  Qatar Med J       Date:  2022-03-04

Review 5.  Adverse Renal Effects of Anticancer Immunotherapy: A Review.

Authors:  Maciej Borówka; Stanisław Łącki-Zynzeling; Michał Nicze; Sylwia Kozak; Jerzy Chudek
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.